Determining the Cell of Origin and Prognostic Gene Signatures in SWOG Trials of Diffuse Large B-Cell Lymphoma
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- SWOG Cancer Research Network
- Enrollment
- 397
- Primary Endpoint
- Differences in PFS between limited- and advanced-stage patients with the GCB and non-GCB phenotypes
Study Overview
Brief Summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies genes in samples from patients with limited and advanced diffuse large B-cell lymphoma.
Detailed Description
OBJECTIVES:
- To determine the proportion of the cell of origin subtypes (germinal center B-cell-like [GCB] vs non-GCB) and expression levels of prognostic genes previously identified in diffuse large B-cell lymphoma (DLBCL) in patient biopsy samples from SWOG trials of limited- and advanced-stage DLBCL, and to assess the association between the results and progression-free survival (PFS).
- To assess the association between these marker results and overall survival (OS).
OUTLINE: Archived formalin-fixed paraffin-embedded tissue are analyzed for gene expression profile by quantitative nuclease protection assay (qNPA) and immunohistochemical analyses. Results are then compared with each patient's progression-free survival and overall survival.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Differences in PFS between limited- and advanced-stage patients with the GCB and non-GCB phenotypes
Time Frame: Retrospectively
Association between GCB markers and OS
Time Frame: Retrospectively
Proportion of GCB phenotype among limited-stage vs advanced-stage patients
Time Frame: Retrospectively
Secondary Outcomes
No secondary outcomes reported